Seattle-based Neoleukin Therapeutics is harnessing protein design technology to develop immunotherapies for cancer, inflammation, and autoimmunity disorders. At the forefront of the company's development is NL-201, a de novo protein designed to imitate the therapeutic activity of cytokines interleukin (IL)-2/IL-15 for treating renal cell carcinoma and melanoma. Formerly known as Aquinox Pharmaceuticals, the biopharmaceutical firm changed its name to Neoleukin Therapeutics in August last year. The company, founded in 2003, aims to carve out its niche in the immunotherapy space.
Neoleukin Therapeutics's ticker is NLTX
The company's shares trade on the NASDAQ stock exchange
They are based in Seattle, Washington
There are 11-50 employees working at Neoleukin Therapeutics
It is neoleukin.com
Neoleukin Therapeutics is in the Healthcare sector
Neoleukin Therapeutics is in the Drug Manufacturers - Other industry
The following five companies are Neoleukin Therapeutics's industry peers: